Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
1 hedge funds and large institutions have $31K invested in Global X China Biotech Innovation ETF in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
97% less capital invested
Capital invested by funds: $1.1M → $31K (-$1.07M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$602K |
| 2 |
Jane Street
New York
|
-$486K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $31K | +$18.2K | +1,056 | +120% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$602K | -32,039 | Closed |
|
|
3
Jane Street
New York
| – | -$486K | -25,874 | Closed |
|
CHB Hedge Fund Activity: Q3 2021 in Review
1 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q3 2021, worth a combined $31K — down 97% from $1.1M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CHB and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $18.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $602K sold.
- 1 institutional investor held Global X China Biotech Innovation ETF (CHB) as of Q3 2021, down from 3 in Q2 2021.
- Funds reported $31K of Global X China Biotech Innovation ETF stock for Q3 2021, down 97% quarter-over-quarter.
- 0 funds opened new Global X China Biotech Innovation ETF positions in Q3 2021 and 2 closed out, a net change of -2 holders.
- The largest Global X China Biotech Innovation ETF buyer in Q3 2021 was UBS Group, an estimated $18.2K added.
- The largest Global X China Biotech Innovation ETF seller in Q3 2021 was Susquehanna International Group, an estimated $602K sold.
Based on aggregated 13F filings for Q3 2021.